文献速递慢阻肺呼吸道感染

呼出气一氧化氮变异性与慢阻肺急性加重风险及病因相关

Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations.
PubMed 文献 · Respirology · 2022-12-26

本研究基于PREVENT研究,对421例接受吸入糖皮质激素/长效β2受体激动剂治疗的慢阻肺患者进行纵向FeNO测定,共2157次访视(1697次稳定期、133次急性加重、327次随访)。结果显示,FeNO个体内变异性在急性加重者中显著高于非加重者(p<0.001),且与急性加重次数正相关;FeNO变异性最高四分位(≥15.0 ppb)患者保持无急性加重的概率仅35%,最低四分位(0.50-4.39 ppb)为80%。从稳定期到急性加重期的FeNO变化与病毒感染概率正相关(现吸烟者更强),与细菌感染概率负相关(仅见于戒烟者)。

要点

  • FeNO个体内变异性越高,慢阻肺急性加重风险越大。
  • FeNO变异性最高四分位患者无急性加重概率仅35%,最低四分位为80%。
  • FeNO变化与急性加重病因的关联在现吸烟者和戒烟者中不同。

核心结论

  • FeNO变异性与慢阻肺急性加重的风险和病因相关,且在现吸烟者和戒烟者中表现不同。

研究设计与样本

  • PREVENT研究为研究者发起的纵向干预研究,纳入421例每日接受吸入糖皮质激素/长效β2受体激动剂治疗的慢阻肺患者,共2157次访视(1697次稳定期、133次急性加重、327次随访)。

主要发现

  • FeNO个体内变异性在急性加重者中显著高于非加重者(p<0.001),且与急性加重次数正相关。
  • FeNO变异性最高四分位(≥15.0 ppb)患者保持无急性加重的概率为35%,最低四分位(0.50-4.39 ppb)为80%。
  • 从最后一次稳定期访视到急性加重访视的FeNO变化与病毒感染概率正相关,现吸烟者中关联更强。
  • 从最后一次稳定期访视到急性加重访视的FeNO变化与细菌感染概率负相关,仅见于戒烟者。

临床怎么用

  • 纵向监测FeNO变异性可能有助于评估慢阻肺患者急性加重风险。
  • FeNO变化结合吸烟状态可能帮助推断急性加重的病因(病毒或细菌)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are heterogeneous in aetiology and accelerate disease progression. Here, we aimed to investigate the association of fractional exhaled nitric oxide (FeNO) and its variability with AECOPD of different aetiology. METHODS: FeNO was determined in 2157 visits (1697 stable, 133 AECOPD and 327 follow-up) of 421 COPD patients from the PREVENT study, an investigator-initiated, longitudinal and interventional study, who were on daily treatment with inhaled corticosteroids/long-acting β2-agonists. RESULTS: Longitudinal measurements of FeNO revealed an intra-subject variability of FeNO that was significantly higher in exacerbators compared to non-exacerbators (p < 0.001) and positively associated with the number of AECOPD. As FeNO variability increased, the probability of patients to remain AECOPD-free decreased. In patients included in the highest FeNO variability quartile (≥15.0 ppb) the probability to remain free of AECOPD was only 35% as compared to 80% for patients included in the lowest FeNO variability quartile (0.50-4.39 ppb). The change of FeNO from the last stable visit to AECOPD was positively associated with the probability of viral infections and this association was stronger in current smokers than ex-smokers. In contrast, the change in FeNO from the last stable visit to an AECOPD visit was inversely associated with the probability of bacterial infections in ex-smokers but not in current smokers. CONCLUSION: FeNO variability was associated with the risk and aetiology of AECOPD differentially in current and ex-smokers.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Schumann, Papakonstantinou, Kostikas, et al. Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations. Respirology. 2022. PMID: 36571108. doi:10.1111/resp.14439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。